Cellectar director granted 25,000 stock options

Cellectar Biosciences director Andrew Gu received a grant of stock options as equity compensation.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cellectar Biosciences director Andrew Gu received a grant of stock options as equity compensation. On July 7, 2026, he was awarded options covering 25,000 shares of common stock with an exercise price of $2.70 per share and an expiration date of July 7, 2036. According to the footnote, the option vests in full on July 7, 2027, provided he continues to serve the company through that date.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Gu Andrew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

F1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Options granted: 25,000 options Exercise price: $2.70 per share Underlying shares: 25,000 shares +3 more

6 metrics

Options granted 25,000 options Grant to director Andrew Gu on July 7, 2026

Exercise price $2.70 per share Stock option exercise price for granted options

Underlying shares 25,000 shares Common stock underlying the stock options

Expiration date July 7, 2036 Option term end date for the grant

Post-grant derivative holdings 25,000 options Total derivative securities following transaction

Vesting date July 7, 2027 Option vests in full, subject to continued service

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Stock option (right to buy) financial

"security_title: "Stock option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "2.7000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-07-07T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common stock""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cellectar Biosciences (CLRB) director Andrew Gu report on this Form 4?

Andrew Gu reported receiving a grant of stock options for 25,000 shares of Cellectar Biosciences common stock. The options are compensation-related, not an open-market purchase, and give him the right to buy shares at a fixed exercise price in the future.

How many Cellectar Biosciences (CLRB) options did Andrew Gu receive and at what price?

Andrew Gu received stock options for 25,000 shares of Cellectar Biosciences common stock. The options have an exercise price of $2.70 per share, meaning he can buy shares at that price once the options are vested and exercisable.

When do Andrew Gu’s Cellectar Biosciences (CLRB) stock options vest and expire?

The option grant to Andrew Gu vests in full on July 7, 2027, if he continues serving the company through that date. The options carry an expiration date of July 7, 2036, after which any unexercised options will lapse.

Is Andrew Gu’s Form 4 for Cellectar Biosciences (CLRB) a stock purchase or compensation grant?

Andrew Gu’s Form 4 reflects a compensation-related grant of stock options, not an open-market stock purchase. The transaction is coded as a grant or award, giving him rights to acquire shares later at a set exercise price of $2.70.

How many Cellectar Biosciences (CLRB) derivative securities does Andrew Gu hold after this grant?

After this reported transaction, Andrew Gu holds 25,000 stock options as derivative securities. These options relate to 25,000 underlying shares of Cellectar Biosciences common stock, all tied to the single grant disclosed in this Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/08/2026 - 09:06 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gu Andrew

(Last)

(First)

(Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK

NEW JERSEY

07932

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$2.7	07/07/2026		A		25,000		⁽¹⁾	07/07/2036	Common stock	25,000	$0	25,000	D

Explanation of Responses:

1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Chad Kolean, attorney-in-fact for Andrew Gu	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR